Loading…
X4 Pharmaceuticals, Inc. is projected to rise to $5.03 by 2027, a +25% move from its current price of $4.03. XFOR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.91 | $4.03 | $4.16 | +0.12% |
| May 30 | $3.86 | $4.04 | $4.22 | +0.24% |
| May 31 | $3.83 | $4.04 | $4.27 | +0.36% |
| Jun 1 | $3.80 | $4.05 | $4.31 | +0.47% |
| Jun 2 | $3.78 | $4.05 | $4.35 | +0.59% |
| Jun 3 | $3.76 | $4.06 | $4.38 | +0.71% |
| Jun 4 | $3.74 | $4.06 | $4.42 | +0.83% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.74 | $4.06 | $4.42 | +0.83% |
| Week 2 | $3.64 | $4.10 | $4.61 | +1.67% |
| Week 3 | $3.57 | $4.13 | $4.77 | +2.52% |
| Week 4 | $3.52 | $4.17 | $4.92 | +3.37% |
| Week 5 | $3.48 | $4.20 | $5.06 | +4.23% |
| Week 6 | $3.45 | $4.24 | $5.20 | +5.09% |
| Week 7 | $3.42 | $4.27 | $5.33 | +5.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
The company has license agreements with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
X4 Pharmaceuticals, Inc. trades under the ticker XFOR in the Healthcare sector. The current price is $4.04 per share, and the company has a market capitalization of $381.05M. Its market rank is 3274.
The near-term outlook comes with a 2026 forecast of min $2.99, avg $4.04, max $6.21 and ROI 0%, with a continued bullish trajectory in subsequent years. From 2027 onward, the forecasts show rising averages and bullish sentiment, culminating in substantial long-range upside through 2050.
A major floor 25.8% below — a decisive break under it would weaken the trend.
The nearest floor, 9.7% below — buyers have tended to step in here.
The nearest ceiling, 11.7% above — a clean break opens room to run.
A major ceiling 22.0% above — clearing it would confirm fresh momentum.
Key XFOR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XFOR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.98 | Buy | $3.99 | Buy |
| MA 10 | $3.94 | Buy | $4.00 | Buy |
| MA 20 | $4.10 | Sell | $4.05 | Sell |
| MA 50 | $4.13 | Sell | $4.05 | Sell |
| MA 100 | $3.90 | Buy | $3.96 | Buy |
| MA 200 | $3.71 | Buy | $4.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.69 | Neutral |
| Stoch RSI (14) | 53.75 | Neutral |
| CCI (20) | -26.90 | Neutral |
| Williams %R (14) | -54.65 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -9.03 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 45.35 | Neutral |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 50.01 | Neutral |
| Momentum (10) | -0.31 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 4.08 | Sell |
| ADX (14) | 9.75 | Neutral |
| ATR (14) | 0.11 | Info |
The sentiment is NEUTRAL. RSI14 is 50. The 50-day simple moving average is $4.11, and the 200-day simple moving average is $3.68. The 30-day price range is $3.24 to $5.04, with a current support level at $3.64 and a resistance at $4.50.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.99 | $4.03 | $6.10 | 0% | Neutral | |
| $3.93 | $5.03 | $6.85 | +25% | Bullish | |
| $4.13 | $5.46 | $7.75 | +36% | Bullish | |
| $4.00 | $5.43 | $7.95 | +35% | Bullish | |
| $3.81 | $5.29 | $7.96 | +31% | Bullish | |
| $4.04 | $5.75 | $8.86 | +43% | Bullish | |
| $4.35 | $6.30 | $9.92 | +56% | Bullish | |
| $5.25 | $7.76 | $12.44 | +93% | Bullish | |
| $5.60 | $8.44 | $13.77 | +109% | Bullish | |
| $5.14 | $7.88 | $13.07 | +96% | Bullish | |
| $7.17 | $11.93 | $21.18 | +196% | Bullish | |
| $10.16 | $19.51 | $38.20 | +384% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.99 | $4.03 | $4.76 | +0.00% |
| June 2026 | $3.65 | $4.30 | $5.20 | +6.66% |
| July 2026 | $3.77 | $4.49 | $5.51 | +4.44% |
| August 2026 | $3.75 | $4.50 | $5.59 | +0.28% |
| September 2026 | $3.85 | $4.64 | $5.82 | +3.11% |
| October 2026 | $4.01 | $4.86 | $6.15 | +4.75% |
| November 2026 | $3.97 | $4.84 | $6.17 | -0.43% |
| December 2026 | $3.88 | $4.75 | $6.10 | -1.84% |
Click any year to see its month-by-month XFOR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
X4 Pharmaceuticals, Inc.'s 2026 outlook centres on $4.03, within a $2.99 to $6.10 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, XFOR could reach as high as $6.85, with a base case around $5.03 and support toward $3.93 — roughly +25% from $4.03. Buyers look set to stay in control over this stretch.
Expect XFOR to range from $4.13 to $7.75 through 2028. The $5.46 average target implies a +36% move from current prices. That is up +9% on the projected 2027 average. Momentum favours further upside here.
The XFOR price prediction for 2029 points to an average of $5.43 (low $4.00, high $7.95) — a potential gain of +35% on today's $4.03. Buyers look set to stay in control over this stretch.
In 2030, XFOR is projected to trade between $3.81 and $7.96, averaging $5.29 — a potential gain of +31% from today's $4.03. That is -3% versus the projected 2029 average. Momentum favours further upside here.
X4 Pharmaceuticals, Inc.'s 2031 outlook centres on $5.75, within a $4.04 to $8.86 range. That is up +9% on the projected 2030 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, XFOR could reach as high as $9.92, with a base case around $6.30 and support toward $4.35 — roughly +56% from $4.03. Momentum favours further upside here.
Expect XFOR to range from $5.25 to $12.44 through 2033. The $7.76 average target implies a +93% move from current prices. That is up +23% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The XFOR price prediction for 2034 points to an average of $8.44 (low $5.60, high $13.77) — a potential gain of +109% on today's $4.03. Momentum favours further upside here.
In 2035, XFOR is projected to trade between $5.14 and $13.07, averaging $7.88 — a potential gain of +96% from today's $4.03. That is -7% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
X4 Pharmaceuticals, Inc.'s 2040 outlook centres on $11.93, within a $7.17 to $21.18 range. That is up +51% on the projected 2035 average. That marks a +196% change versus current levels. Momentum favours further upside here.
By 2050, XFOR could reach as high as $38.20, with a base case around $19.51 and support toward $10.16 — roughly +384% from $4.03. Buyers look set to stay in control over this stretch.
Investing $1,000 in XFOR today (≈ 248.138958 XFOR) could be worth
$4,841.74
+$3,841.74 (+384%) by 2050 · US Dollar
Based on the average projected XFOR price of $19.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XFORwould be worth at today's price.
$1,000 invested in XFOR on May 27, 2025 (≈ 294.985242 XFOR) would be worth
$1,188.79
+$188.79 (+18.9%) today · 1.19× · US Dollar
Based on a XFOR entry price of $3.39 vs. today's $4.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.77 | $1,068.97 | +6.9% |
| 1 month ago | $4.21 | $957.24 | -4.3% |
| 3 months ago | $3.25 | $1,240 | +24.0% |
| 6 months ago | $3.64 | $1,107.14 | +10.7% |
| 1 year ago | $3.39 | $1,188.79 | +18.9% |
| All time (5.0y) ago | $285 | $14.14 | -98.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XFOR forecast.
Our base-case forecast reaches $8.10 around 2034.
Implied market cap at $8.10: $763.99M
The multi-year forecast shows a path of gradual appreciation with mixed early-year volatility. In 2026, the avg is $4.04 and the price range spans from $2.99 to $6.21, with a 0% ROI. By 2027 the avg rises to $5.10 and by 2028 to $5.46, with continued bullish sentiment and higher max values through 2029 ($8.03) and 2030 ($7.98).
From 2031 to 2035, the averages climb further (2031 $5.60, 2032 $6.18, 2033 $7.64, 2034 $8.25, 2035 $7.72) as sentiment remains bullish. The 2040 forecast shows a notable step up to an avg of $11.54 with a max of $20.91 and a high ROI of 185.6%, followed by a 2050 avg of $18.75, a max of $37.62 and an ROI of 364.1%.
These figures are estimates and not guarantees. The outlook reflects the provided forecast data, including bullish sentiment in later years, but actual outcomes will depend on market conditions and other factors.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $5.23, a low of $3.71, and a high of $7.98, with an ROI of 29.4% and a BULLISH sentiment.
Forecasts show bullish sentiment from 2027 onward, with 2027 avg $5.10, 2028 avg $5.46, 2029 avg $5.41, 2030 avg $5.23, 2040 avg $11.54, and 2050 avg $18.75, with ROI rising to 364.1%.
According to the forecast, 2040 shows an avg of $11.54 and a max of $20.91, indicating potential to exceed $10 under the forecast.
For 2026, min $2.99, avg $4.04, max $6.21, ROI 0%, sentiment NEUTRAL.
The 30-day range is $3.24 to $5.04. The 50-day simple moving average is $4.11, and the 200-day simple moving average is $3.68.
X4 Pharmaceuticals, Inc. Community Discussion
0Share your X4 Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.